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Abstract
Rheumatoid arthritis is an autoimmune disorder involving the chronic inflammation of
affected joints which lead to the distortion and eventually destruction of the articular
tissues. Clinically, many therapeutic methods are being used for RA treatment. Non-
steroidal anti-inflammatory drugs (NSAIDs), steroid, and disease-modifying anti-
rheumatic drugs (DMARDs) are the three main categories of intervention approaches.
Among which DMARDs, targeting mainly the release of pro-inflammatory cytokines,
demonstrated high efficacy because of its direct drug action that alter the underlying
disease mechanisms rather than simply to mediate symptoms relieve. However, the use
of DMARDs also accompanying some unwanted adverse side effects, in particular, the
development of refractoriness, which hampers the successful rate of treatment. In this
chapter, the conventional RA drugs will be reviewed, focusing on the currently used and
latest development of DMARDs. Novel methods that could improve RA pathogenesis will
also be introduced. Because of the critical role of refractory RA, the progress of the disease
to develop resistance to standard drug treatment will also be described. Finally, innova-
tive RA therapeutic methods inspired by researches concerning the pathogenesis and
contemporary treatments of RA will be discussed.
Keywords: rheumatoid arthritis, DMARDs, refractory, immunotherapy,
immunosuppressive
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1. Introduction
Around 0.5–1% of the world population is challenged by rheumatoid arthritis (RA) with patients
afflicted by progressive articular destruction accounting for the commonest chronic systemic
autoimmune disorder [1, 2]. RA is demonstrating prevalence in developed countries or urban
areas [3] and is around three times more commonly found in female [4]. Apart from persistent
synovitis, structural bone damages, and the eventual deformity of affected joints, 40% of the RA
patients are also accompanied with extra-articular manifestations in multiple organs including
kidney (glomerulonephritis), heart (atherosclerosis), and skin (small vessel vasculitis) [5, 6]
critically compromising the quality of life [7]. Owing to the comparatively early disease onset
(at the age between 30 and 50) [8], RA also implied increased individual and socioeconomic
impact as a result of reduced work capacity and early unemployment [9–11].
Thus far, the etiology of RA is unclear and curing strategy is lacked. Environmental and
genetic factors are considered as the main causes of increased risk of RA. Smoking is the
strongest environmental stimuli that trigger the onset of RA. Both cohort and case-control
studies demonstrated that the number and duration of cigarette consumption is positively
correlated to RA risk in a dose dependent and irreversible manner [12, 13]. By contrast, the
use of alcohol significantly reduced RA susceptibility in habitual drinkers when compared
with non-drinkers or individuals consuming low level of alcohol [14, 15]. In the case of
smoking-induced RA, the involvement of polymorphisms in genes mechanistically regulating
the immunity, such as the human leukocyte antigen-DRB1 (HLA-DRB-1)-encoded type II major
histocompatibility complex (MHC), is critical to more than half of such condition [7]. Of note,
some of the disease-associated polymorphic variants of HLA-DRB-1 are specific to severe
disease phenotypes, for example, more aggressive erosive disease and higher mortality [16].
Genetic involvement in RA is also suggested by the existence of shared epitope of RA-
associated circulatory autoantibodies such as the IgG rheumatoid factor (RF) and antibodies
recognizing the citrullinated peptide [7]. Although not all RA patients are positive for IgG- and
citrullinated peptide-recognizing autoantibodies, the heritability rate of RA is approximately
40–65% for seropositive rheumatoid arthritis, and 20% for seronegative disease [17, 18].
The pathogenesis of RA is as complicated as the causation of the disorder, conventional
therapeutic methods is not confined to the application of single pharmaceutical intervention.
Instead, personalized treatment algorithms with the combinational use of different RA medi-
cations are required, which is highly dependent on individual patient and the stage of disease
progression. Generally the drug used for RA can be classified into three categories: (1) non-
steroidal anti-inflammatory drugs (NSAIDs); (2) glucocorticoid (steroid); (3) non-biological
(synthetic origin)/biological disease-modifying anti-rheumatic drugs (DMARDs). The thera-
peutic effects of NASIDs like aspirin and Coxibs targeting the cyclooxygenase pathways,
together with glucocorticoid acting via the cortisol receptor, are rapid which effectively allevi-
ate the analgesic, pyretic, and inflammatory symptoms associated with RA [19, 20]. However,
the effects of NASIDs are limited to symptoms relief and demonstrated no significant delaying
effect on disease progression [21]. Glucocorticoids can slow down the progress of bone erosion
resulted from cytokines-induced imbalance of local bone turnover under long-term treatment
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with low dosage [22]. Unfortunately, the extensive side effects affecting the different organs
outweighed such beneficial immunosuppressive property. As such, therapeutic compounds,
for example the treat-to-target DMARDs, which control the inflammatory and destructive
processes of RA is inevitable to the maintenance of persistent remission. Since, DMARDs is
slow-acting drug which take 1 month to a year to be effective [23], NSAIDs/glucocorticoid are
usually applied together with DMARDs to serve initially as moderator of pain and stiffness
before the drug action of DMARDs commence.
Many DMARDs have previously been reported targeting various cellular signaling molecules
or receptors related to the immunoregulatory machinery of RA. In this chapter, the currently
employed, as well as newly exploited DMARDs will be described. The latest therapeutic
strategies that can potentially be applied to RA intervention will also be updated. Eventually,
insight provided by such methods that could innovate novel RA therapeutic development will
be discussed.
2. Innate and adaptive immunity in the pathogenesis of RA
Inflammation and swelling of the synovial membrane, or synovitis, are the pathological fea-
tures of RA. Both the innate and adaptive immunity are participating the disease pathogenesis
through the orchestration of cellular communication between the two systems. The pathogen-
esis of RA is heterogeneous (Figure 1) and the exact triggering factors of the inflammatory
Figure 1. Cellular and molecular pathogenesis of RA: (A) Gross anatomical structure of the inflamed joint of RA. (B) The
inflammatory synovium with cytokine signaling and cellular interactions underlying the RA pathogenesis indicated. (C)
The involvement of lymph node in orchestrating the activation of immunocellular components involved in RA progres-
sion. TCR: T cell receptor; APC: Antigen presenting cells; FLS: Fibroblast-like synoviocyte; MHCII: Major hoistocom-
patibility complex class II.
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response at the diseased joint are still unclear. In the inflammatory milieus, the synovial
macrophages (SM) positioned at the cartilage–pannus junction is activated to secret the pro-
inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-1, and 6 (IL-1/IL-6). In
fact, findings suggested that the SM are the key regulator of RA inflammation [24]. These
cytokines then activate another important residential cell type, the fibroblast-like synoviocytes
(FLS), in the synovium leading to hyperproliferation and the consequential formation of an
abnormal layer of fibrovascular tissue called pannus. The pannus expresses the cytokine
receptor activator of nuclear factor kappa-Β ligand (RANKL) which together with the
macrophage-released cytokines, stimulate the differentiation of osteoclast [25] to resorb the
calcified bone matrix (i.e. bone erosion) via the secretion of acid and hydrolytic enzymes such
as cathepsin K and matrix metalloproteinase-13 (MMP-13). In addition, the activation of FLS in
pannus generates proteinases that are correlated to the destruction of cartilage [1, 26]. The
activated FLS also migrate to other unaffected joints and induce inflammatory responses and
bone and cartilage destruction [27].
Infiltrated antigen-driven CD4+ lymphocytes and plasma cells (c.a. 50% and 5% of lympho-
cytes found in synovium, respectively) are also found in the inflamed joints. The RA joints are
highly vascularized due to the inflammation-induced angiogenesis, and that the newly gener-
ated blood vessels facilitate the infiltration of the lymphocytes from the periphery. In the
synovium, CD4+ lymphocytes secreted a repertoire of cytokines, including IL-17, which fur-
ther stimulate the expression of inflammatory mediators from SM and FLS supporting the
persistent inflammatory environment of the affected joints. The plasma cells also involve in
such process by the secretion of different cytokines. One of the activation routes of the infil-
trated CD4+ lymphocytes and plasma cells is via the cell-cell interaction with the antigen
presenting cells (APC), for example dendritic cells (DC). Environmental factors, like smoking
and genetic abnormalities and chronic inflamed RA tissues can induce the modification,
including citrullination, of autoantigens, such as citrullinated self-proteins of vimentin, alpha-
enolase, fibronectin, and type II collagen [28], which activated the APC to generate the surface
MHC-peptide complex. The autoantigen-activated APC migrate to the secondary lymphoid
organs (SLO) and stimulate the maturation of CD4+ T lymphocytes via the MHC-peptide
complex and co-stimulatory molecules, such as CD80/CD86, on the cellular surface [29]. B
lymphocytes in the germinal center are then co-stimulated by the mature CD4+ T lymphocytes
to become plasma cells which produce the destructive autoantibodies, such as RF and anti-
citrullinated protein antibodies (ACPAs) [30, 31]. These CD4+ T lymphocytes, plasma cells, and
autoantibodies eventually return to the RA joints mediating the destructive process of bone
and cartilage and underpinning the chronic inflammatory response.
3. Conventional and current development of DMARDs for RA treatment
The intricate interaction between the immunocellular components during RA progression
suggested that the effective regulation targeting the signaling mediators of such cellular com-
munication or the physiology of the involved immune cells appeared as the key to successful
RA therapy. Several FDA-approved DMARDs, for example Methotrexate, TNF antagonists,
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Rituximab, and Tocilizumab, which modify the biologic responses are extensively used as
immunotherapy for preventing immune attacks associated with RA in clinical settings.
3.1. Methotrexate (MTX)
MTX is among the quickest-acting DMARDs and represent the mainstay of DMARDs ther-
apy. As a non-biologic DMARDs, MTX is produced through chemical synthesis which is
structurally analogous to folate inhibitory targeting the dihydrofolate reductase (DHFR)
[32] which is critical to the de novo synthesis of purine and pyrimidine, therefore, down-
regulate cellular proliferation and induce apoptosis. MTX-induced inhibition of DHFR also
leads to the generation of resultant polyamines which is accumulated and converted into
toxic ammonia and hydrogen peroxide by synovial mononuclear cells in RA patients func-
tionally suppressing the stimulated T lymphocytes [33]. As expected, MTX suppress the
proliferation and inhibit the turnover of inflammatory cells during RA treatment [34]. How-
ever, the mechanism of action of MTX is complex which is not merely mediated through
limiting the growth and survival of the immunocellular components. MTX also target and
inhibit 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase leading
eventually to the increased intra and extra-cellular levels of adenosine [35, 36], which con-
tributed significant to adenosine-induced immunosuppression [37] as demonstrated by the
inhibition of phagocytosis, secretion of TNF, IFN, IL2, IL12, expression of HLA expression,
etc. [38–43]. Findings also evident the indirect anti-inflammatory and inhibited neutrophil
chemotaxis effects of MTX signaling via the cyclooxygenases-2 (COX-2) and lipoxygenase
pathways [44–46]. In the synovial tissue, MTX also indirectly inhibit the synthesis of
metalloproteinase (MMP) and activate tissue inhibitor of MMP (TIMP) via cytokines (IL-1)
modulation [47].
3.2. Tocilizumab (TCZ)
The monoclonal antibody TCZ, together with TNF and CD20 antagonists [48] which will be
discussed later, represented the subcategory of biologic DMARDs, is produced through
genetic engineering as contrast to the chemically synthesized non-biologic counterpart. The
biologic DMARDs exhibit their therapeutic effect in a treat-to-target manner by modulating
the various molecular pathways signaling the dysregulated immunity. As the first of its kind,
TCZ specifically target the IL-6 receptor (IL-6R) by functioned as an antagonist [49] and is
usually used when conventional treatment (e.g. MTX) [50, 51] and other biologic DMARDs
(e.g. TNF antagonists) become irresponsive or tolerated [52]. However, TCZ also works with
high efficacy when applied as monotherapy in early disease [53]. In the course of RA patho-
genesis, serum and synovial tissue levels of IL-6 is elevated and is positively correlated to RA
disease severity and radiological joint damage [54–57]. Mechanistically, IL-6 coupled with
IL-6R triggering the Janus kinase (JAK) pathways [58] and activates the downstream effector
functions of the different RA-associated immune cells. For example, IL-6 stimulates the
plasmablasts to produce autoantibodies [59] and significantly regulates the differentiation pro-
cess of T lymphocytes by enhancing T helper 17 (Th17)/regulatory T lymphocytes (Treg) balance
skewed toward the Th17 profile [60]. In addition, IL-6 are involve in the proliferation and
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production of MMP of FLS [56, 61] and differentiation of osteoclast [62], which lead to cartilage
damages and bone resorption. TCZ can downregulate these RA-associated cellular responses by
interacting with the IL-6R. New findings suggested that the therapeutic effects of TCZ can be
mediated by lowering the serum level of IL-6, however, the underpinning mechanisms are yet to
be defined [63].
3.3. TNF antagonists
Infliximab, etanercept, and adalimumab are the currently approved TNF antagonists being
used clinically in RA treatment [23]. These type of DMARDs are sharing similar efficacy as
MTX exhibiting rapid drug response [64, 65]. When compared with MTX, the mechanism of
action of these inhibitors are more specific which target to the tumor necrosis factor receptor
type 1 and 2 (TNFR1/TNFR2) signaling pathways mediated by the cytokine tumor necrosis
factor-alpha (TNF-α) [64, 65]. Cells with monocytic origin are the main cellular components
producing TNF-α [66], however, other immune cell types , for example lymphoid and mast
cells, has also been reported to participate the secretory process [23]. During the course of RA
pathogenesis, TNF-α serves as a strong chemoattractant for the tethering of neutrophils to the
endothelial cells [67]. Also, TNF-α is the central regulator of the immunity which autocrinally
and paracrinally repress the expression of other cytokines, such as IL-1, IL-6, IL-8, and granu-
locyte colony-stimulating factor (G-CSF) [68]. Therefore, the blockage of TNF signaling with
the use of TNF antagonists can molecularly suppress the pro-inflammatory progression of RA
in a systemic sense. The three TNF antagonists are recombinant monoclonal antibodies that
function by binding either to TNF-α (infliximab) or the corresponding receptor (etanercept and
adalimumab). Clinically, the use of TNF inhibitors in conjugation with MTX at the initial stage
of RA is associated with rapid disease remission [69].
3.4. Rituximab (RTX)
Similar to TCZ and TNF antagonists, RTX is a chimeric monoclonal antibody recognizing the
antigen CD20 which is a transmembrane receptor expressed on the surface B lymphocytes
during differentiation from the pre-B cell to memory B cell stages [70, 71]. As previously
mentioned, B lymphocytes are contributing to the development of RA via the production of
autoantibodies. The B lymphocytes also produce a spectrum of pro-inflammatory cytokines,
including IL-6, IL-16, TNF-α, and lymphotoxin-β (LT-beta) [72, 73], which are pivotal to the
perpetuation of inflammatory environment aggravating joint damage. Therefore, the use of
RTX to deplete CD20+ B lymphocytes suggested an effective therapeutic strategy for RA. The
antibody binds to the cell surface protein CD20 and induces cell death toward the targeted B
lymphocytes via three potential pathways: (1) Antibody dependent cell-mediated cytotoxicity
(ADCC) which stimulates phagocytosis and cell lysis of CD20+ lymphocytes by the binding of
immunocellular components, such as macrophages, monocytes, and natural killer cells, via the
Fcγ region of RTX [74, 75]; (2) Complement dependent cytotoxicity (CDC) by inducing mem-
brane attack toward CD20+ B lymphocytes resulted in cell lysis via the formation of rituximab-
complement (C1q) complexes [76]; (3) Direct promotion of CD20+ B cell apoptosis [77]. It is
worth noting that, CD20 neither present on stem cells nor the antibody-secreting plasma cells
which enhance the safety of the practical application of RTX. Although the monoclonal antibody
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is approved for use in combination with MTX, current study reported that RTX is efficient and
safe for managing RA patients without the presence of MTX [78].
3.5. The development of novel DMARDs
The mentioned FDA-approved DMARDs (both biologic and non-biologic) are demonstrating
profound effects in RA intervention. Owing to the chronic nature of RA, however, patients are
subjected to prolonged exposure of DMARDs resulted in the development of side effects and
drug resistance. For the use of MTX, hepatic fibrosis or cirrhosis is one of the most severe side
effects affecting the patients [33]. Skin and soft tissue infections and abnormal liver function are
observed in patients treated with TCZ [53]. TNF antagonists have been reported to associate
with adverse responses such as serious bacterial and opportunistic infections, and lymphoma
[79–81]. RTX treatment is also plagued by severe skin reaction and infection [23]. Accordingly,
researchers have been making efforts to improve the toxicity of classical DMARDs and to exploit
of newer anti-rheumatic agents.
In 2007, a polypeptide-based novel TNF antagonist with amino acid sequence isolated from
part of the pre-ligand assembly domain (PLAD) has been patented [82]. In the extra-cellular
region of TNFR, PLAD is located at the position NH2-terminal to the ligand binding domain
essential for inducing receptors trimerization. The binding of the synthetic polypeptide to
PLAD elicit inhibition to the formation of functional receptors complex and repress the down-
stream signaling thereof. Such therapeutic peptide inhibitor is recognized by the immune
system as “totally-self” and is highly specific instead of blocking immunocomponents in a
global sense, therefore, avoiding undesirable immune reactions minimizing the appearance of
potent adverse side effects [83]. A patent application of another 18-residue peptide targeted the
secretory phospholipase A2 (sPLA2) has also been filed [84]. As a pro-inflammatory mediator,
sPLA2 is found to be related to the onset and severity of RA in animal [85] and patients [86],
respectively. The neovascularization process which is critical to the RA-associated hyperplasia
of synovial tissue has been suggested as therapeutic target for the development of novel
DMARDs as well. The cytokines that are significantly responsible for new blood vessel out-
growth is vascular endothelial growth factor (VEGF) which also participates to vascular
leakage [87]. VEGF inhibitory compounds, such as derivatives of quinazoline [88, 89], have
been synthesized and can potentially be used for RA treatment. There are still many others
new DMARDs, for example, the colony-stimulating factor (CSF) inhibitors, which target the
key regulator of neutrophil production [90, 91]. All these compounds are potentially new
therapeutic strategy with high efficacy and improved adverse effects. Investigation of the
combinational use of these compounds with the classical DMARDs will also encourage the
discovery of formulation against refractory RA for patients who respond poorly to conven-
tional interventions.
4. Next-generation immunosuppressive strategies
In general, the described DMARDs directly inhibit the pro-inflammatory signaling molecules
and their receptors. The ligand-receptor interaction is circumvented by the use of monoclonal
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antibodies, synthetic peptides, or natural compounds. These therapeutic strategies tune down
the cytokines machinery of the targeted cells or manipulate the cells that produce the cytokines
lead eventually to RA remission. Theoretically, any immunosuppressive methods, not limited
to interfering the ligand-receptor interaction process, can result in therapeutic effects toward
RA and innovate the development of RA treatment.
4.1. Sphingosine-1-phosphate receptors (S1PRs) agonist
Antagonizing the recruitment of immunocellular components to reach the site of inflammation
provided a clue to RA treatment. Chemokine receptors such as CCR5 and CXCR3 are playing
significant roles in RA pathogenesis via the regulation of monocyte and T lymphocyte chemo-
taxis [92, 93]. The use of inhibitors against these receptors has shown therapeutic efficacy
toward RA treatments [94, 95]. Instead of blockage of immune cells from entering the inflam-
matory site, to enhance the homing of these cells could be another approach for controlling the
inflammatory status of RA joints. Fingolimod (FTY720), an analog of sphingosine-1-phosphate
(S1P) extracted from a vegetative wasp composed of the fruiting bodies of Isaria sinclairii and
its parasitic host larva [96], is able to deplete lymphocytes from the circulatory and lymphatic
systems [97, 98]. The mechanism of action involves the formation of phosphorylated FTY720
(FTY720-P) by sphingosine kinase 2 which agonistically stimulates the sphingosine-1-
phosphate receptors (S1PRs). Located on the surface of lymphocytic cells, S1PR is internalized
upon interaction with FTY720-P inhibiting lymphocytes egress from the secondary lymphoid
tissues and thymus (lymphopenia). As such, the FTY720-treated lymphocytes are sequestrated
in the lymph nodes, spleen, and thymus, which are not able to recirculate to peripheral
inflammatory tissues. In fact, the migration of other immune cells are also regulated by the
S1P-S1PRs axis, for example, dendritic cells (DCs) [99] and macrophages [100]. FTY720 is
originally used for allotransportation to induce long-term graft acceptance [101] reflecting the
pharmaceutical value of the immunosuppressive property of the compound. In fact, FTY720-
induced lymphopenia has been proposed as a new therapeutic approach for RA as demon-
strated in the adjuvant-induced arthritis (AIA) rat [102]. In a recent animal experiment using
the collagen-induced arthritis (CIA) model, it was revealed that the migration profile of DCs is
also modulated by FTY720 and is responsible for the beneficial effects of the treatment [103].
Most importantly, the normal function of the immune cells is preserved after FTY720 treatment
[100, 104], suggesting the safety and practicality in the application of the compound.
4.2. Dendritic cell (DCs)-targeted therapeutics
As a key regulator of both the innate and adaptive immunity, DCs in the inflamed synovial
tissues of RA plays a significant role in the pathomechanism. In RA patients, DCs are activated
in response to pro-inflammatory cytokines stimulation, with up-regulated co-stimulatory mol-
ecule expression [105]. DCs also induce the differentiation of Th1 and Th17 cells via production
of IL-12 and IL-23 [106]. Also, treatment with TNF-α inhibitors could reduce the number of
activated DCs and inhibits its maturation, leading to improvement of the clinical symptoms of
RA [107]. These observations support the strategy of targeting DCs for the treatment of RA.
Accordingly, DCs with tolerogenic function has been proposed as therapeutic tool for RA
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treatment, which specifically targets the pathogenic autoimmune response and simultaneously
maintain the integrity of protective immunity [108]. In a randomized, unblinded, placebo-
controlled, dose-escalation phase I study, tolerogenic DC therapy demonstrates promising
results in RA patients without major adverse effects. However, administration of tolerogenic
DC therapy should ideally be given to RA patient as early as possible, to avoid the establish-
ment of autoimmunity desensitizing the RA treatment [109].
4.3. Manipulation of neuroimmune communication
The reciprocal effects of the nervous system on immunity have attracted high focus. The
nervous system regulates inflammation via a variety of neurotransmitters, neuropeptides,
and peripheral nerves. In general, activation of sympathetic nervous system may exhibit both
pro-inflammatory and anti-inflammatory properties, whereas the para-sympathetic nervous
system via the vagus nerve, exerts anti-inflammatory actions [110]. Subsequent research has
identified the neuronal type α7-acetylcholine (Ach) receptor is necessary to regulate the anti-
inflammatory effects mediated by the para-sympathetic nervous system [111]. Interestingly,
the α7-ACh receptors are also widely expressed in immune cells and FLS [112, 113]. TNF-α
expressed by the residential macrophages in spleen located in the red pulp and marginal zone
can be repressed via the stimulation of vagus nerve mediated by nicotinic acetylcholine
receptor subunit α7 [114]. Accordingly, administration of a specific α7-ACh receptor agonist
showed effective inhibition of systemic inflammatory responses in CIA models [115, 116]. In
animal models of neurological disorders, peripheral denervation suppressed joint inflamma-
tion in mice with AIA has also been demonstrated [117]. Recently a clinical trial consolidated
that vagal nerve stimulation (VNS) could be therapeutically feasible in RA. VNS refers to the
technique of manually or electrically stimulates the vagus nerve, which has been approved
more than a decade ago by the FDA for the treatments of severe and recurrent unipolar and
bipolar depression [118], as well as pharmaco-resistant epilepsy [119]. The potential use of
VNS for insomnia, anxiety, etc., have also been reported [120]. Clinical relevance of VNS in RA
was debuted in 2012 in which a volunteer patient with surgically implanted pacemaker-like
nerve stimulator successfully halted the joints attack with remarkable symptoms recovery
[121]. It was proved to be a result of VNS-stimulated inhibition of peripheral blood production
of TNF, IL-1β, and IL-6 in a later clinical study [122]. Such achievement posited the alternative
use of computerized device in RA treatment as compared to the traditional biological or
chemical pharmaceutics
4.4. Cell-based therapy
The modulation of disease pathogenesis by the delivery of cellular materials to patients has
been proposed as promising intervention method for many incurable conditions [123]. The
application of mesenchymal stem cells (MSCs) is the prototype among the various types of
cell-based therapy, which illustrated another possibility of managing RA without using the
biological or chemical pharmaceutics. MSCs are capable of bypassing the sanction of immune
system upon transplantation [124, 125] conferring the practicality per se to act as potential
allograft by abolishing the concomitant requirement of immunosuppressant drugs. A recent
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randomized, single-blind, placebo-controlled phase Ib/IIa clinical trial has been established to
evaluate the safety and tolerability of intravenously administrating the Cx611, a preparation of
allogeneic expanded adipose-derived MSCs (eASCs), in patients with refractory RA [126].
Results demonstrated that patients were having good response and generally well tolerated
the infused Cx611 without evidence of dose-related toxicity at the dose range and time period
studied. The precise mechanisms mediating the beneficial effects of Cx611 is not clear, it could
be associated with the interruption of T lymphocytes and SLF pathophysiology including
inhibited cellular proliferation and inflammatory cytokines production, enhanced generation
of anti-inflammatory cytokines, and antigen-specific T lymphocytes [127–129]. The allogeneic
nature of Cx611 in this study circumvents the limitation of using patient-specific clinical grade
stem cell product with unstable availability during manufacture making itself an “off-the-
shelf” therapeutic product [130]. Provided that, the isolation and expansion procedures of
MSCs are comparatively easy, which further secured their supply during immediate need
[123]. On top of that, the limited replicative lifespan of MSCs provided additional safety by
avoiding the formation of unwanted malignancy [123].
5. From intervention to innovation: Implication of conventional and
emerging RA therapies on the exploitation of novel immunosuppressive
strategies against refractoriness
Conventional DMARDs, both the non-biologic and biologic types, are able to achieve clinical
remission or reduce disease activity status for RA. Nevertheless, the unmet need in the treat-
ment of RA remains high because of substantial number of RA patients do not response
sufficiently to the currently available regimens. Therefore, remission of disease is not always
achieved and refractory cases are very common [131, 132]. The causes of refractory RA are
multifaceted varying depend on individual, patient-tailored management approach is
presented to determine whether persistence of signs and symptoms is based on the inflamma-
tory disease activity, and the role of comorbidities [133]. Owing to the complexity in etiology of
refractory RA, it is difficult to summarize a single picture that can comprehensively depict the
underpinning cellular responses and molecular pathways. Here in this section, some of the
possible causative factors that may responsible for the development of resistance against
standard RA treatment are to be listed. Ingenious intervention methods for refractory RA as
inspired by the increasingly understanding of the disorders will also be discussed.
5.1. P-glycoprotein (P-gp)-mediated drug resistance
P-gp, also known as multidrug resistance protein 1 (MDR1) or CD243, is an important mem-
brane pumps for the cellular removal of foreign substances. In patients with refractory RA and
high disease activity, overexpression of P-gp on lymphocytes can cause resistance to anti-
rheumatic drugs through efflux of intracellular drugs [134]. Recent studies further showed
that high expression level of P-gp found in FLS of refractory RA patients is the potential
mechanism for multidrug resistance in RA treatment [135]. Also, activated B lymphocytes with
elevated P-gp expression seems to be associated with drug resistance, disease activity, and
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destructive arthritis with extra-articular involvement in RA [136]. Overcoming drug resistance
by using P-gp inhibitor could sensitize the response to DMARDs in patients with refractory
RA further support the role of P-gp in the development of refractoriness [137].
5.2. Autoantibodies-mediated refractoriness
Although the direct association of autoantibodies and refractory RA is enigmatic, RA patients
with more severe disease and a worse prognosis are seropositive for RF and ACPAs [138, 139].
Patients with unsatisfactory responsiveness toward conventional DMARs, in particular MTX,
resumed clinical improvement after TNF antagonists treatment through the manipulation of
autoantibodies level, which represent a promising therapeutic method for refractory RA to other
treatment options [140–142]. In a one-year prospective study with the use of adalimumab
(monoclonal anti-TNF-α antibody), MTX-resistant patients are clinically benefited from the
treatment in terms of decreased tender/swollen joint counts, erythrocyte sedimentation rate,
and C-reactive protein values associated with RF and ACPAs titer reduction [143]. Treatment
using another monoclonal antibody infliximab against TNF-α also demonstrated clinical efficacy
toward patients who do not respond to DMARDs by decreasing the serum levels of RF and
ACPAs [144]. Of note, the efficacy of TNF antagonists is correlated to the titers of both RF and
ACPAs. The higher the autoantibodies titer, the lower is the clinical response of the anti-TNF-
agents [145]. These findings strongly suggested that autoantibodies generation during the course
of RA pathogenesis may lead to the progression to refractoriness.
5.3. Role of cytokines in refractory RA development
Regardless the profound effects of TNF antagonists in refractory RA treatment, many patients
either do not respond or relapse after initially responding to these agents [146]. Recent study
revealed that the responsiveness of anti-TNF-α agents in RA patients depend on high blood
level of granulocyte–monocyte colony-stimulating factor (GM-CSF) and low blood level of
IL-17. Circulatory lymphocytes from most anti-TNF-α responder patients produced higher
levels of GM-CSF than non-responder patients, whereas non-responsiveness to anti-TNF-α is
associated with high IL-17 levels suggest that the responsiveness of TNF-α inhibitors is likely
to be driven by different inflammatory pathways [146].
5.4. Current drugs and therapeutic approaches for refractory RA
As MTX is the first-line and frequently used DMARD, it is one of the most studied compounds
for RA therapy. Information concerning the development of and the method to overcome drug
resistance of MTX is well documented. Only about 40-60% of RA patients compromise with the
MTX monotherapy [147]. Combination therapeutic approaches are commonly adopted and
found effective in clinic, especially with MTX combined with other anti-arthritic agents. For
instance, CsA, sulfasalazine, LEF, doxycycline, and HCQ individually combined with MTX
demonstrated good efficacy in clinic, whereas triple DMARD therapy (MTX-sulfasalazine-chlo-
roquine) and step-up combination of four DMARDs (MTX-CsA-HCQ-prednisone) are also
applied in clinical treatment of RA [147–149]. However, a new synthetic small-molecule DMARD
called iguratimod was recommended to treat RA patients who showed inadequate response to
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MTX-CsA-HCQ-prednisone treatment [147]. Another immunosuppressive drug, tacrolimus
(TAC) was found to be a promising therapeutic option for refractory RA patients despite treat-
ment with anti-TNF therapy combined with methotrexate [150]. Later study further demon-
strated the new oral triple combination therapy using TAC with MTX and mizoribine (MZR),
this oral triple therapy might be safe and economical for clinical practice in effective against
refractory RA [151]. Unfortunately, combination therapy is not always working and drug-
resistant cases are still commonly found in refractory RA patients [147]. Therefore, the search of
novel therapeutic strategies to combat refractoriness of RA is still urged.
5.5. Innovative therapeutic strategies for refractory RAwith clinical potential
As mentioned in the earlier section, the use of monoclonal anti-CD20 antibody RTX is one of
the approved conventional therapeutic methods for RA for the co-treatment with MTX. A
randomized, double-blind controlled clinical trial indicated the potent efficacy of low dose
RTX in RA refractory to first-line DMARD, MTX [148]. In addition, a recent clinical study has
evaluated the impact of RTX on patient-reported outcomes (PROs) in a US-based observa-
tional cohort of patients with active RA refractory to TNF-α antagonist. Results demon-
strated that patients with long-standing refractory RA experienced improvements in PROs
1 year after initiating RTX [152]. Another clinical study further revealed that RTX-based B
cell depletion therapy is effective in refractory RA and systemic lupus erythematosus (SLE)
[153]. Together with the role of CD20+ plasma cells in autoantibodies production, deletion of
B lymphocytes with specific identity of surface antigen appeared to be a prominent therapy
for tackling refractory RA. In 2017, a new kind of immunotherapy, namely chimeric antigen
receptor (CAR)-T cell therapy, has been approved by FDA for the cancers of acute lympho-
blastic leukemia and advanced lymphomas [154], which provide insight to the exploitation
of novel tool for B lymphocytes removal. The concept of CAR-T cell therapy involves the
genetically engineering of autologous T lymphocytes to express a chimeric antigen receptor
of target. Accordingly, expressing the CAR that recognized CD20 for RA therapy, in princi-
pal, can preserve the same effects as monoclonal anti-CD20 antibody. Another surface anti-
gen CD19 has also been suggested as a promising marker for targeting B lymphocyte in RA
[155] , which can also serve as another CAR-T cell therapeutic target. The humoral responses
of B lymphocytes isolated from RA patients are repressed by the administration of the
monoclonal anti-19 antibody XmAb5871 which facilitate the engagement of CD19, B cell
antigen receptor, and Fcγ receptor IIb inhibitory receptor [156]. When compared with the
passive administration of monoclonal antibody, CAR-T cells are benefited from its tissue
biodistribution property because of their extravasate capacity [157], active responses to
chemokine signaling [158], and the secretory ability of proteolytic enzymes [159]. Also, the
self-amplification property of CAR-T cells enhance their in vivo persistence after adoptive
transfer [160, 161].
On the other hand, the therapeutic effects toward RA by S1P-induced lymphopenia and VNS
suggested the development of intervention methods by means of systemic regulation of the
immunity. Intriguingly, the gut-associated lymphoid tissue (GALT) represent the largest mass
of lymphoid tissue in the human body, which is an immune hub intimately communicating with
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residential microbiome to maintain the homeostatsis of different organs [162]. The involvement
of gut microbiome in the systemic dysregulation of host immunity in different disease as a result
of disturbed phyletic distribution or amount in the gut environment has aroused tremendous
attention. Evidence associating gut microbiome and RA has recently been documented based on
the characterization of the expansion of rare lineage intestinal microbes in RA [163]. Also, a
metagenome-wide association study (MGWAS) suggested that the dysbiosis of gut microbial
detected in RA is associated with clinical indices, which can be partly normalized after DMARDs
treatment [164]. These information tempted us to ask if the application of pharmaceutic or health
care supplement which manipulate the microbiome physiology could be potential RA therapeu-
tic approach for providing more effective treatment with fewer side effects [165]. Chinese herbal
medicine (CHM) appeared to be an ideal pharmaceutical method accordingly, since the philoso-
phy of traditional Chinese medicine (TCM) emphasized on the maintenance of holistic balance of
the human bodywhich is best fit to the idea of managing local inflammation via the regulation of
systemic immune system. In addition, CHM is natural constituents of herbal plant, and have
been used for centuries, which is comparatively safe for clinical trial. In China, the country with
wide application of CHM, medicinal compounds extracted from herbal plant has been using as
folk remedy to manage RA for a long time. Many herbal formulated drugs targeting RA are
prescribed in clinics, for example, Qingfu Guanjiesu capsule and Zhengqing Fengtongning tablet
exploited by our group are demonstrating good clinical efficacy. The single molecule sinomenine
is the main bioactive component constituting the above two pharmaceutics, which can success-
fully inhibit the proliferation of activated lymphocytes [166]. Our recent studies further
suggested that the mechanism of action of sinomenine is cell type-oriented and is targeting
multiple signaling pathways. Sinomenine suppresses the proliferation of FLS by regulating
α7nAChR expression [167]. It also downregulates the expression of mPGES-1, which lead to the
alleviation of arthritic inflammation [168]. Of note, sinomenine inhibits mPGES-1 transcription
without affecting prostacyclin (PG)I2 and thromboxane (TX)A2 synthesis, therefore, lowering
the risk of cardiovascular complication upon treatment. As yet, report documented CHM usage
in RA by targeting gut microbiome is scarce. However, it is suggested that CHM can maintain
the homeostasis of the gut ecosystem mainly via two processes [169]: (1) metabolic manipulation
of the administrated CHM by gut microbiota; (2) gut microflora-targeted modulation of physio-
logical conditions. The possibility of practising CHM to manipulate gut microbiota has been
demonstrated in a recent case study using the decoction Du-Shen-Tang containing ginseng
polysaccharides and ginsenosides [170]. The administration of Du-Shen-Tang, after gut
microbiota-involved metabolism, was able to recover the pathologically ablated gut microbiota
and specifically stimulated the growth of the commensal Lactobacillus spp. and Bacteroides spp. As
such, CHM that could similarly modulate the gut-microbes as polysaccharides and ginsenosides
decotion, may enhance the immune system and ultimately intervent the refractory condition.
6. Conclusion
Although a lot of intervention methods are available for the treatment of RA, they often come
along with drug resistance upon unavoidable persistent administration. In addition, the
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long-term usage of RA drugs is often associated with various side effects which complicated
the treatment performance. Therefore, the search for novel therapeutic approaches is needed
so as to explore more effective RA medication. Such new drugs could enlarge the pharma-
ceutical scope of choices for refractory cases by acting as monotherapeutic agent or being
used in combination with other conventional RA drugs. Of note, the novel findings related to
the control, or more precisely, the regulation of local joint inflammatory profile via systemic
immune system deserved more attention and in-depth investigation. Since, researches in
such orientation could provide information not just for the cure of RA, but also, hopefully,
could help to achieve the goal of disease prevention.
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